Qube Research & Technologies (QRT)
AMLX icon

Qube Research & Technologies (QRT)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,600
Closed -$44.3K – 3758
2024
Q1 		$44.3K Buy
+15,600
New +$204K ﹤0.01% 3529

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AMLX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Amylyx Pharmaceuticals (AMLX) stake by 3% in Q2 2026, selling an estimated $322K and leaving 681,389 shares worth $12.2M. The position accounts for 0.01% of the portfolio, ranked #1178.

Qube Research & Technologies (QRT) first reported a position in AMLX in Q1 2023 and has held it in 14 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 681,389 shares of Amylyx Pharmaceuticals worth $12.2M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 20,847 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $322K.
  • Amylyx Pharmaceuticals made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1178 holding.
  • Qube Research & Technologies (QRT) first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.